Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics

Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics: the MACADAMIA Pilot Study

The purpose of this research is to see if information from blood and data from smartwatches can be combined to help diagnose depression and determine if transitions between active depression and treated depression can be predicted.

Study Overview

• Status: Enrolling by invitation
• Conditions: Major Depressive Disorder; Unipolar, Non-psychotic Major Depressive Disorder

• Study Type: Observational
• Enrollment (Estimated): 40

Contacts and Locations

Study Locations

• United States
  • Florida
    • Jacksonville, Florida, United States, 32224
      • Mayo Clinic Florida

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Subjects will be recruited from an ongoing cohort study at Mayo Florida "Wearable Augmented Prediction of Burnout in Nurses: A Synergy of Engineering, Bioethics, Nursing and Wellness Sciences" (BROWNIE Study)

Description

Inclusion Criteria:

• Participated in the BROWNIE study.
• DSM-5 diagnostic criteria are met for unipolar, non-psychotic MDD (excluding controls).
• A score of > 10 on the QIDS-C and QIDS-SR (equivalent to 13 or greater on HAM-D17) given that when medication exceeds the effect of placebo in primary care participants have a HAM-D17 >12 (excluding controls).
• Antidepressant treatment is deemed appropriate by a study clinician (excluding controls).
• Smart watch wear time is at least 70% during their participation in the BROWNIE study.

Exclusion Criteria:

• Subjects with medical contraindications that preclude treatment with study drugs will be excluded.
• Patients with schizophrenia, schizoaffective disorder, or who have bipolar I or II disorder (or another specified or unspecified bipolar spectrum disorder) will be excluded because they have a primary psychiatric condition that requires a different initial treatment.
• Subjects currently on antidepressant medication with subtherapeutic results in terms of depression management will undergo a medication taper and discontinuation prior to initiation of a new study medication. The subject will be closely monitored by the study clinician during the medication taper and discontinuation phase. The medication taper is left up to the study clinician's discretion. Study subjects who cannot be safely tapered from their medication or experience adverse effects during the taper will be excluded from the study.
• Subjects who have an active substance use disorder will be excluded. An active substance use disorder will be defined as meeting DSM-5 diagnostic criteria for any active substance use disorder. Persons meeting DSM-5 diagnostic criteria for a substance use disorder in full remission (>12 months) and a negative urine drug of abuse screen at the screening visit or before the baseline study visit will be considered eligible. Persons with a positive urine drug of abuse screen may participate in the study if they do not meet DSM-5 diagnostic criteria for a substance use disorder.
• Subjects unable to give informed consent or who are unwilling or unable to comply with study requirements are excluded.
• Pregnant subjects will be excluded.
• Subjects who are currently breastfeeding and who plan to continue breastfeeding will be excluded.
• Subjects who are psychiatrically hospitalized or in a mental health crisis requiring urgent care or psychiatric hospitalization.
• Study subjects currently on antipsychotic medications (e.g., typical, and atypical antipsychotic drugs) taken for primary psychotic illness or affective psychosis will be excluded.
• Study subjects taking mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) taken specifically for bipolar spectrum disorders are not eligible for participation.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Non-depressed controls; Subjects without depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.
Antidepressant-treated adults; Subjects diagnosed with depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Quick Inventory of Depressive Symptoms-Clinician Rated (QIDS-CR) scale	The Quick Inventory of Depressive Symptoms-Clinician Rated is used for rating the severity of depressive symptoms. Possible scores range from 0 to 27, with higher scores indicating greater severity of depression.	Baseline, 4 weeks, and 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Hamilton Depression Rating Scale	The Hamilton Depression Rating Scale is used for rating the severity of depressive symptoms. Possible scores range from 0 to 50, with higher scores indicating greater severity of depression.	Baseline, 4 weeks, and 8 weeks

Collaborators and Investigators

• Sponsor: Mayo Clinic
• Collaborators: Florida State University
• Investigators: Principal Investigator: Mohit Chauhan, MBBS, Mayo Clinic

Publications and helpful links

Helpful Links

• Mayo Clinic Clinical Trials

Study record dates

Study Major Dates

• Study Start (Actual): August 2, 2023
• Primary Completion (Estimated): June 6, 2026
• Study Completion (Estimated): December 6, 2026

Study Registration Dates

• First Submitted: June 11, 2023
• First Submitted That Met QC Criteria: June 11, 2023
• First Posted (Actual): June 20, 2023

Study Record Updates

• Last Update Posted (Actual): August 3, 2025
• Last Update Submitted That Met QC Criteria: July 30, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Behavioral Symptoms; Mood Disorders; Depression; Depressive Disorder; Depressive Disorder, Major
• Other Study ID Numbers: 23-002931

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No